<DOC>
	<DOCNO>NCT02871882</DOCNO>
	<brief_summary>To study effect ileocolonic formulation ox bile extract insulin sensitivity , postprandial glycemia incretin level , gastric emptying , body weight fast serum FGF-19 ( fibroblast growth factor ) level overweight obese type 2 diabetic subject therapy DPP4 ( dipeptidyl peptidase-4 ) inhibitor ( e.g . sitagliptin ) alone combination metformin .</brief_summary>
	<brief_title>Ox Bile- Conjugated Bile Acids Sodium Type II Diabetes Mellitus</brief_title>
	<detailed_description>This single-center , placebo-controlled , parallel-group , single dose , randomize , control trial . Participants receive 28 day ( +/- 4 day ) treatment study effect delay ( ileocolonic ) -release ox bile extract 500 mg BID ( twice daily ) insulin sensitivity , gastric empty liquid solid ( measure scintigraphy ) weight loss I overweight obese type 2 diabetic subject . Participants receive therapy DPP4 inhibitor alone combination metformin . Blood sample collect defined time measure glycemia , FGF-19 incretins ( GLP-1 [ glucagon-like peptide-1 ] , OXM [ oxyntomodulin ] , PYY 3-36 [ peptide YY ] ) fasting level responses meal .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>Inclusion criterion : 1 . Overweight obese subject BMI &gt; 30 kg/m2 type 2 diabetes mellitus take DPP4 inhibitor alone combination metformin . 2 . Women childbearing potential negative pregnancy test initiation medication within 48 hour receive radioisotope . Exclusion criterion : 1 . Structural metabolic diseases/conditions affect gastrointestinal system , functional gastrointestinal disorder . 2 . Irritable bowel syndrome 3 . Bristol stool type classification 47 per Bowel Disease questionnaire . 4 . Subjects treatment type 2 diabetes mellitus . 5 . Subjects HbA1c &gt; 8 % 6 . Females pregnant breastfeed 7 . Concomitant use appetite suppressant , orlistat , phenterminetopiramate ER lorcaserin . 8 . Subjects currently treatment cardiac , pulmonary , gastrointestinal , hepatic , renal , hematological , neurological , endocrine ( type 2 diabetes mellitus ) , unstable psychiatric disease . 9 . Subjects donate blood plasma past 8 week . 10 . Subjects participate another study within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>